RxDoctor Payments Data

Rohan Devanpalli Ramaya, MD

Internal Medicine · Creve Coeur, MONPI 1396057535

Payments from drug & device makers

$1,470in general payments, 2019–2025

Across 58 payments — averaging $25.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$327
  • Travere Therapeutics, Inc.$322
  • Vifor Pharma, Inc.$199
  • Otsuka America Pharmaceutical, Inc.$142
  • Vantive US Healthcare LLC$130
  • Nxstage Medical, Inc.$105
  • plus $245 from 5 others

What the payments were for

  • Food & beverage$1,43698%
  • Education$342%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,470 in reported general payments places this provider in the 75th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$189,774
Medicare patients
438
Services billed
1,563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VeltassaPatiromer Calcium Sorbitex19$34,919
FarxigaDapagliflozin Propanediol28$29,210
ProsolParenteral Amino Acid 20% No.138$5,216
Nifedipine ErNifedipine87$1,960
Torsemide105$1,598
Midodrine Hcl15$840
Olmesartan Medoxomil15$766
Losartan Potassium102$756
Tamsulosin Hcl40$607
Hydralazine Hcl50$396
Calcitriol34$370
Potassium Chloride15$224
Chlorthalidone14$151
Amlodipine Besylate51$146
Metoprolol Succinate11$143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$327$29,21028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Creve Coeur

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →